Cited by 2,029RNA Research and SplicingAcute Myeloid Leukemia ResearchGenomics and Rare Diseases

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Frequent pathway mutations of splicing machinery in myelodysplasia

Yoshida, Kenichi, Sanada, Masashi, Shiraishi, Yuichi, Nowak, Daniel, Nagata, Yasunobu, Yamamoto, Ryo, Sato, Yusuke, Sato-Otsubo, Aiko, Kon, Ayana, Nagasaki, Masao, Chalkidis, George, Suzuki, Yutaka, Shiosaka, Masashi, Kawahata, Ryoichiro, Yamaguchi, Tomoyuki, Otsu, Makoto, Obara, Naoshi, Sakata-Yanagimoto, Mamiko, Ishiyama, Ken, Mori, Hiraku, Nolte, Florian, Hofmann, Wolf-Karsten, Miyawaki, Shuichi, Sugano, Sumio, Haferlach, Claudia, Koeffler, H. Phillip, Shih, Lee-Yung, Haferlach, Torsten, Chiba, Shigeru, Nakauchi, Hiromitsu, Miyano, Satoru, Ogawa, Seishi·2011·Nature

DOI 10.1038/nature10496

Open this paper in CoChat — free account

Abstract

Myelodysplastic syndromes and related disorders (myelodysplasia) are a heterogeneous group of myeloid neoplasms showing deregulated blood cell production with evidence of myeloid dysplasia and a predisposition to acute myeloid leukaemia, whose pathogenesis is only incompletely understood. Here we report whole-exome sequencing of 29 myelodysplasia specimens, which unexpectedly revealed novel pathway mutations involving multiple components of the RNA splicing machinery, including U2AF35, ZRSR2, SRSF2 and SF3B1. In a large series analysis, these splicing pathway mutations were frequent (∼45 to ∼85%) in, and highly specific to, myeloid neoplasms showing features of myelodysplasia. Conspicuously, most of the mutations, which occurred in a mutually exclusive manner, affected genes involved in the 3'-splice site recognition during pre-mRNA processing, inducing abnormal RNA splicing and compromised haematopoiesis. Our results provide the first evidence indicating that genetic alterations of the major splicing components could be involved in human pathogenesis, also implicating a novel therapeutic possibility for myelodysplasia.

Integrity signals

Registry

Crossref · 10.1038/nature10496

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
The Spliceosome: Design Principles of a Dynamic RNP Machine
Wahl, M. C., Will, C. L., & Lührmann, R. (2009) · Cell · doi:10.1016/j.cell.2009.02.009 · Cited by 2,665
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,457
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 601–700 of 1,002

RNA Splicing: A New Player in the DNA Damage Response
Lenzken, S. C., Loffreda, A., & Barabino, S. M. L. (2013) · International Journal of Cell Biology · doi:10.1155/2013/153634 · Cited by 48
Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy
Hahn, C. N., Venugopal, P., Scott, H. S., & Hiwase, D. (2014) · Immunological Reviews · doi:10.1111/imr.12241 · Cited by 46
Identification of DNA methylation changes atcis-regulatory elements during early steps of HSC differentiation using tagmentation-based whole genome bisulfite sequencing
Lipka, D. B., Wang, Q., Cabezas‐Wallscheid, N., Klimmeck, D., Weichenhan, D., Herrmann, C., Lier, A., Brocks, D., von Paleske, L., Renders, S., et al. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973334 · Cited by 49
Splice isoforms as therapeutic targets for colorectal cancer
Miura, K., Fujibuchi, W., & Unno, M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs347 · Cited by 46
Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
Liu, B., Liu, Z., Chen, S., Ki, M., Erickson, C., Reis-Filho, J. S., Durham, B. H., Chang, Q., de Stanchina, E., Sun, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138315 · Cited by 49
Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia
Rivera, O. D., Mallory, M. J., Quesnel-Vallières, M., Chatrikhi, R., Schultz, D., Carroll, M. P., Barash, Y., Cherry, S. R., & Lynch, K. W. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014967118 · Cited by 46
R-loop and its functions at the regulatory interfaces between transcription and (epi)genome
Kim, A., & Wang, G. G. (2021) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2021.194750 · Cited by 46
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
Bland, P. J., Saville, H., Wai, P. T., Curnow, L., Muirhead, G., Nieminuszczy, J., Ravindran, N., John, M. B., Hedayat, S., Barker, H. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01460-5 · Cited by 48
Refractory anemia with ring sideroblasts and RARS with thrombocytosis
Patnaik, M. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24038 · Cited by 45
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
Kulasekararaj, A. G., Mohamedali, A. M., & Mufti, G. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12435 · Cited by 47
Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia
Matsunawa, M., Yamamoto, R., Sanada, M., Sato‐Otsubo, A., Shiozawa, Y., Yoshida, K., Otsu, M., Shiraishi, Y., Miyano, S., Isono, K., et al. (2014) · Leukemia · doi:10.1038/leu.2014.73 · Cited by 49
Self-citation
The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia
Sutton, L., & Rosenquist, R. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.04.009 · Cited by 47
Splicing controls the ubiquitin response during DNA double-strand break repair
Pederiva, C., Böhm, S., Julner, A., & Farnebo, M. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.58 · Cited by 45
Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia
Ping, N., Sun, A., Song, Y., Wang, Q., Yin, J., Cheng, W., Xu, Y., Wen, L., Yao, H., Ma, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.162 · Cited by 47
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms
Mori, T., Nagata, Y., Makishima, H., Sanada, M., Shiozawa, Y., Kon, A., Yoshizato, T., Sato‐Otsubo, A., Kataoka, K., Shiraishi, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.212 · Cited by 45
Self-citation
Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT
Berger, G., Kroeze, L. I., Koorenhof‐Scheele, T. N., de Graaf, A. O., Yoshida, K., Ueno, H., Shiraishi, Y., Miyano, S., van den Berg, E., Schepers, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805879 · Cited by 45
Self-citation
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis
Jafari, P. A., Ayatollahi, H., Sadeghi, R., Sheikhi, M., & Asghari, A. (2018) · Hematology · doi:10.1080/10245332.2018.1471794 · Cited by 45
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk‐stratification, and Management”
Patnaik, M. M., & Tefferi, A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25397 · Cited by 46
MicroRNA21 and the various types of myeloid leukemia
Panagal, M., R., S. K. S., Sivakurunathan, P., Biruntha, M., Karthigeyan, M., Gopinathe, V., Sivakumare, P., & Sekar, D. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0025-2 · Cited by 44
GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies
Benbarche, S., Pineda, J. M. B., Galvis, L. D. B., Biswas, J., Liu, B., Wang, E., Zhang, Q., Hogg, S. J., Lyttle, K. A., Dahi, A., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.006 · Cited by 45
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
Cervera, N., Itzykson, R., Coppin, E., Prébet, T., Murati, A., Legall, S., Vey, N., Solary, É., Birnbaum, D., & Gelsi‐Boyer, V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23702 · Cited by 46
Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia
Wang, C., Sashida, G., Saraya, A., Ishiga, R., Koide, S., Oshima, M., Isono, K., Koseki, H., & Iwama, A. (2014) · Blood · doi:10.1182/blood-2013-12-544544 · Cited by 49
The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression
Shilo, A., Siegfried, Z., & Karni, R. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.970955 · Cited by 45
A new class of protein cancer biomarker candidates: Differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines
Omenn, G. S., Guan, Y., & Menon, R. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.04.012 · Cited by 44
Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing
Cazzola, M., & Malcovati, L. (2015) · Hematology · doi:10.1182/asheducation-2015.1.19 · Cited by 45
RNA structure in splicing: An evolutionary perspective
Lin, C., Taggart, A. J., & Fairbrother, W. G. (2016) · RNA Biology · doi:10.1080/15476286.2016.1208893 · Cited by 44
To be red or white: lineage commitment and maintenance of the hematopoietic system by the “inner myeloid”
Kato, H., & Igarashi, K. (2019) · Haematologica · doi:10.3324/haematol.2019.216861 · Cited by 47
Targeting BRD9 for Cancer Treatment: A New Strategy
Zhu, X., Liao, Y., & Tang, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s286867 · Cited by 45
U2af1 is required for survival and function of hematopoietic stem/progenitor cells
Dutta, A., Yang, Y., Le, B. T., Zhang, Y., Abdel-Wahab, O. I., Zang, C., & Mohi, G. (2021) · Leukemia · doi:10.1038/s41375-020-01116-x · Cited by 47
Wilms’ tumor 1-associating protein complex regulates alternative splicing and polyadenylation at potential G-quadruplex-forming splice site sequences
Horiuchi, K., Kawamura, T., & Hamakubo, T. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101248 · Cited by 46
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 45
Mutations in SETBP 1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression
Fernández‐Mercado, M., Pellagatti, A., Genua, C. D., Larráyoz, M. J., Winkelmann, N., Aranaz, P., Burns, A., Schuh, A., Calasanz, M. J., Cross, N. C. P., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12491 · Cited by 43
Genomic Sequencing for Cancer Diagnosis and Therapy
Wang, L., & Wheeler, D. A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120811-171056 · Cited by 44
Pathogenesis of Myeloproliferative Disorders
Nangalia, J., Grinfeld, J., & Green, A. R. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044454 · Cited by 48
Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.
Zahid, M. F., Malik, U. A., Sohail, M., Hassan, I. N., Ali, S., & Shaukat, M. H. S. (2017) · PubMed Central · Cited by 45
Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment
Lin, J.-C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010075 · Cited by 43
Pan-cancer analysis identifies mutations in SUGP1 that recapitulate mutant SF3B1 splicing dysregulation
Liu, Z., Zhang, J., Sun, Y., Perea-Chamblee, T. E., Manley, J. L., & Rabadán, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922622117 · Cited by 45
Structural insights into branch site proofreading by human spliceosome
Zhang, X., Zhan, X., Bian, T., Yang, F., Li, P., Lu, Y., Xing, Z., Fan, R., Zhang, Q. C., & Shi, Y. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01188-0 · Cited by 42
The Spliceosome as an Indicted Conspirator in Myeloid Malignancies
Abdel-Wahab, O. I., & Levine, R. L. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.004 · Cited by 43
Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions
Muramatsu, H., Makishima, H., & Maciejewski, J. P. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.004 · Cited by 42
Genomics of Acute Myeloid Leukemia: The Next Generation
Riva, L., Luzi, L., & Pelicci, P. G. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00040 · Cited by 42
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
Chesnais, V., Renneville, A., Toma, A., Lambert, J., Passet, M., Dumont, F., Chevret, S., Lejeune, J., Raimbault, A., Stamatoullas, A., et al. (2015) · Blood · doi:10.1182/blood-2015-04-640128 · Cited by 47
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
Negoro, E., Radivoyevitch, T., Polprasert, C., Ademà, V., Hosono, N., Makishima, H., Przychodzen, B. P., Hirsch, C., Clemente, M. J., Nazha, A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.228 · Cited by 43
The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia
Zheng, G., Chen, P., Pallavajjalla, A., Haley, L. M., Gondek, L. P., Dezern, A. E., Ling, H., Marchi, F. D., Lin, M., & Gocke, C. D. (2019) · American Journal of Hematology · doi:10.1002/ajh.25592 · Cited by 42
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Palomo, L., Ibáñez, M., Abáigar, M., Vázquez, I., Álvarez, S., Cabezón, M., Tazón‐Vega, B., Rapado, I., Fuster‐Tormo, F., Cervera, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16175 · Cited by 44
The functional mechanisms of mutations in myelodysplastic syndrome
Nagata, Y., & Maciejewski, J. P. (2019) · Leukemia · doi:10.1038/s41375-019-0617-3 · Cited by 42
Self-citation
Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
Panuzzo, C., Signorino, E., Calabrese, C., Ali, M. S., Petiti, J., Bracco, E., & Cilloni, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030802 · Cited by 43
Computing the Role of Alternative Splicing in Cancer
Liu, Z., & Rabadán, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.015 · Cited by 43
Large-scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers
Feusier, J. E., Arunachalam, S., Tashi, T., Baker, M. J., Vansant-Webb, C. H., Ferdig, A., Welm, B. E., Rodríguez-Flores, J. L., Ours, C., Jorde, L. B., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0094 · Cited by 45
Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish
Weinreb, J. T., Gupta, V., Sharvit, E., Weil, R., & Bowman, T. V. (2021) · Haematologica · doi:10.3324/haematol.2020.257246 · Cited by 43
Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities
Blijlevens, M., Li, J., & van Beusechem, V. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105110 · Cited by 43
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS)
Berman, E., Jhanwar, S., Hedvat, C., Arcila, M. E., Wahab, O. A., Levine, R., Maloy, M., Ma, W., & Albitar, M. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.006 · Cited by 41
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML
Wheeler, E. C., Martin, B. J. E., Doyle, W. C., Neaher, S., Conway, C. A., Pitton, C. N., Gorelov, R. A., Donahue, M. K., Jann, J. C., Abdel-Wahab, O. I., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade2774 · Cited by 42
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)
Mohamedali, A. M., Gäken, J. A., Ahmed, M., MALIK, F., Smith, A., Best, S., Mian, S. A., Gaymes, T. J., Ireland, R. M., Kulasekararaj, A. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.110 · Cited by 42
Chronic Myeloid Leukemia Stem Cell Biology
Crews, L. A., & Jamieson, C. H. M. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0121-6 · Cited by 43
RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation
Shimoni-Sebag, A., Lebenthal-Loinger, I., Zender, L., & Karni, R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt247 · Cited by 42
Aberrant splicing in maize rough endosperm3 reveals a conserved role for U12 splicing in eukaryotic multicellular development
Gault, C. M., Martin, F., Mei, W., Bai, F., Black, J. B., Barbazuk, W. B., & Settles, A. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616173114 · Cited by 41
Splicing dysregulation as a driver of breast cancer
Read, A., & Natrajan, R. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0068 · Cited by 41
Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis
Kim, S. K., Takeda, H., Takai, A., Matsumoto, T., Kakiuchi, N., Yokoyama, A., Yoshida, K., Kaido, T., Üemoto, S., Minamiguchi, S., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01555-z · Cited by 42
Self-citation
Recent insights regarding the molecular basis of myeloproliferative neoplasms
Jang, M., & Choi, C. W. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.317 · Cited by 42
Therapeutic manipulation of IKBKAP mis-splicing with a small molecule to cure familial dysautonomia
Ajiro, M., Awaya, T., Kim, Y. J., Iida, K., Denawa, M., Tanaka, N., Kurosawa, R., Matsushima, S., Shibata, S., Sakamoto, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24705-5 · Cited by 42
Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes
Xu, F., Wu, L., Chang, C., He, Q., Zhang, Z., Liu, L., Shi, W.-H., Guo, J., Zhu, Y., Zhao, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms9806 · Cited by 41
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms
Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., Gekas, C., Heiser, D., & Greenberg, P. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001934 · Cited by 40
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review
Vegivinti, C. T. R., Keesari, P. R., Veeraballi, S., Maia, C., Mehta, A. K., Lavu, R. R., Thakur, R., Tella, S. H., Patel, R. J., Kakumani, V. K., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00422-1 · Cited by 43
Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)
Ohba, R., Furuyama, K., Yoshida, K., Fujiwara, T., Fukuhara, N., Onishi, Y., Manabe, A., Ito, E., Ozawa, K., Kojima, S., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1564-5 · Cited by 40
Self-citation
Refractory anemia with ring sideroblasts
Malcovati, L., & Cazzola, M. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.09.005 · Cited by 40
Expression analysis in a rat psychosis model identifies novel candidate genes validated in a large case–control sample of schizophrenia
Ingason, A., Giegling, I., Hartmann, A. M., Genius, J., Konte, B., Friedl, M., Ripke, S., Sullivan, P. F., Clair, D. S., Collier, D. A., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.151 · Cited by 41
Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells
Morita, K., Noura, M., Tokushige, C., Maeda, S., Kiyose, H., Kashiwazaki, G., Taniguchi, J., Bando, T., Yoshida, K., Ozaki, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16799-z · Cited by 40
Self-citation
Impaired Spermatogenesis, Muscle, and Erythrocyte Function in U12 Intron Splicing-Defective Zrsr1 Mutant Mice
Horiuchi, K., Pérez‐Cerezales, S., Papasaikas, P., Ramos‐Ibeas, P., López‐Cardona, A. P., Laguna‐Barraza, R., Balvís, N. F., Pericuesta, E., Fernández‐González, R., Planells, B., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.028 · Cited by 40
Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology
Vivet-Noguer, R., Tarin, M., Roman‐Roman, S., & Alsafadi, S. (2019) · Cancers · doi:10.3390/cancers11071019 · Cited by 43
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
Skov, V. (2020) · Cancers · doi:10.3390/cancers12082194 · Cited by 40
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
Huber, S., Haferlach, T., Meggendorfer, M., Hütter, S., Hoermann, G., Baer, C. R., Kern, W., & Haferlach, C. (2022) · Leukemia · doi:10.1038/s41375-022-01728-5 · Cited by 42
Self-citation
Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape
Boddu, P. C., Gupta, A. K., Roy, R., Avalos, B. D. L. P., Olazabal‐Herrero, A., Neuenkirchen, N., Zimmer, J. T., Chandhok, N. S., King, D. P., Nannya, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.02.032 · Cited by 41
Self-citation
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
Cui, Y., Tong, H., Du, X., Li, B., Gale, R. P., Qin, T., Liu, J., Xu, Z., Zhang, Y., Huang, G., et al. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0009-y · Cited by 39
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
Thol, F. R., Yun, H., Sonntag, A.-K., Damm, F., Weissinger, E. M., Krauter, J., Wagner, K., Morgan, M. A., Wichmann, M., Göhring, G., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1457-7 · Cited by 40
Self-citation
Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia
Reinig, E. F., Yang, F., Traer, E. A., Arora, R., Brown, S., Rattray, R. M., Braziel, R. M., Fan, G., Press, R. D., & Dunlap, J. B. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw016 · Cited by 41
Regulatory Potential of the RNA Processing Machinery: Implications for Human Disease
Carey, K. T., & Wickramasinghe, V. O. (2018) · Trends in Genetics · doi:10.1016/j.tig.2017.12.012 · Cited by 39
Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations
Jiang, Y., Eveillard, J., Couturier, M., Soubise, B., Chen, J., Gao, S., Basinko, A., Morel, F., Douet‐Guilbert, N., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13030481 · Cited by 41
PHF6 Mutations in Hematologic Malignancies
Kurzer, J. H., & Weinberg, O. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704471 · Cited by 41
RNase H1, the Gold Standard for R-Loop Detection
Cerritelli, S. M., Sakhuja, K., & Crouch, R. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2477-7_7 · Cited by 41
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
Bejar, R. L. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0270-5 · Cited by 40
RNA-binding proteins in pluripotency, differentiation, and reprogramming
Guallar, D., & Wang, J. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1326-y · Cited by 39
Sororin pre‐mRNA splicing is required for proper sister chromatid cohesion in human cells
Watrin, E., Demidova, M., Watrin, T., Hu, Z., & Prigent, C. (2014) · EMBO Reports · doi:10.15252/embr.201438640 · Cited by 39
Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours
Simon, J., Perez‐Rivas, L. G., Zhao, Y., Chasseloup, F., Lasolle, H., Cortet, C., Descôtes, F., Villa, C., Baussart, B., Burman, P., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad114 · Cited by 38
Splicing factor mutations in myelodysplasia
Ogawa, S. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1182-y · Cited by 38
Self-citation
Expression profiling of leukemia patients: Key lessons and future directions
Shivarov, V. S., & Bullinger, L. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.04.006 · Cited by 40
Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy
Pasquier, F., Cabagnols, X., Secardin, L., Plo, I., & Vainchenker, W. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.06.014 · Cited by 45
Prognostic models in myelodysplastic syndromes
Bejar, R. L. (2013) · Hematology · doi:10.1182/asheducation-2013.1.504 · Cited by 38
Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus
Singh, N., Traisak, P., Martin, K. A., Kaplan, M. J., Cohen, P. L., & Denny, M. F. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4681 · Cited by 38
Functional characterization of a novel GFI1B mutation causing congenital macrothrombocytopenia
Kitamura, K., Okuno, Y., Yoshida, K., Sanada, M., Shiraishi, Y., Muramatsu, H., Kobayashi, R., Furukawa, K., Miyano, S., Kojima, S., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13350 · Cited by 38
Self-citation
Integrating mutation variant allele frequency into clinical practice in myeloid malignancies
Sallman, D. A., & Padron, E. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.04.003 · Cited by 39
Preclinical modeling of myelodysplastic syndromes
Rouault‐Pierre, K., Mian, S. A., Goulard, M., Abarrategi, A., Tullio, A. D., Smith, A., Mohamedali, A., Best, S., Nloga, A.-M., Kulasekararaj, A. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.172 · Cited by 43
Genetic and transcriptional landscape of plasma cells in POEMS syndrome
Nagao, Y., Mimura, N., Takeda, J., Yoshida, K., Shiozawa, Y., Oshima, M., Aoyama, K., Saraya, A., Koide, S., Rizq, O., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0348-x · Cited by 39
Self-citation
A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex
Chatrikhi, R., Feeney, C. F., Pulvino, M. J., Alachouzos, G., MacRae, A. J., Falls, Z., Rai, S., Brennessel, W. W., Jenkins, J. L., Walter, M. J., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.007 · Cited by 38
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 42
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
Lee, P., Yim, R., Yung, Y., Chu, H.-T., Yip, P.-K., & Gill, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910232 · Cited by 40
Failure to Detect Mutations in U2AF1 due to Changes in the GRCh38 Reference Sequence
Miller, C. A., Walker, J., Jensen, T. L., Hooper, W. F., Fulton, R. S., Painter, J. S., Sekeres, M. A., Ley, T. J., Spencer, D. H., Goll, J. B., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.10.013 · Cited by 40
The genomic landscape of chronic lymphocytic leukemia: clinical implications
Quesada, V., Ramsay, A. J., Rodrı́guez, D., Puente, X. S., Campo, E., & López-Otı́n, C. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-124 · Cited by 39
Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory
Kanagal‐Shamanna, R., Singh, R. R., Routbort, M. J., Patel, K. P., Medeiros, L. J., & Luthra, R. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1142374 · Cited by 40
Somatic SETBP1 mutations in myeloid neoplasms
Makishima, H. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2241-1 · Cited by 38

Authors: Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.-K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H. P., Shih, L.-Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S., & Ogawa, S.
Affiliations: The University of Tokyo (JP)
Institute of Medical Science, The University of Tokyo (JP)
Heidelberg University (DE)
Japan Science and Technology Agency (JP)
University of Tsukuba (JP)
Tokyo Metropolitan Ohtsuka Hospital (JP)
SHOWA Medical University Fujigaoka Hospital (JP)
Munich Leukemia Laboratory (Germany) (DE)
Cedars-Sinai Medical Center (US)
Chang Gung University (TW)
Corresponding author: Ogawa, Seishi
ORCID: Yoshida, Kenichi
Sanada, Masashi
Shiraishi, Yuichi
Nowak, Daniel
Nagata, Yasunobu
Sato, Yusuke
Kon, Ayana
Nagasaki, Masao
Suzuki, Yutaka
Yamaguchi, Tomoyuki
Otsu, Makoto
Obara, Naoshi
Ishiyama, Ken
Nolte, Florian
Miyawaki, Shuichi
Sugano, Sumio
Haferlach, Claudia
Koeffler, H. Phillip
Shih, Lee-Yung
Haferlach, Torsten
Chiba, Shigeru
Nakauchi, Hiromitsu
Miyano, Satoru
Ogawa, Seishi
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2011-09-11
Volume: 478
Issue: 7367
Pages: 64-69
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10496
OpenAlex: W2073889874
Cited by: 2,029
References: 37
Citations by year: 2026: 71 · 2025: 76 · 2024: 121 · 2023: 101 · 2022: 139 · 2021: 160 · 2020: 148 · 2019: 135 · 2018: 135 · 2017: 148 · 2016: 146 · 2015: 145 · 2014: 173 · 2013: 171 · 2012: 135
FWCI: 64.98
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Japan Society for the Promotion of Science (22390191, 23791075, 22790895, 23659533, 23659482, 23390269, 23791068, 22659058)
National Cancer Institute (R01CA026038)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: myelodysplastic syndrome, splicing mutation, U2AF35, ZRSR2, SRSF2, SF3B1, 3' splice site recognition, pre-mRNA splicing, hematopoiesis, acute myeloid leukemia, myeloid neoplasms, aberrant splicing, therapeutic target
MeSH terms: Splicing Factor U2AF, Hematopoiesis, Humans, Mutation, Myelodysplastic Syndromes, Nuclear Proteins, Ribonucleoproteins, RNA Splicing, Spliceosomes, Alternative Splicing, Polymorphism, Single Nucleotide, RNA Splice Sites, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Frequent pathway mutations of splicing machinery in myelodysplasia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks